Brian Neel - Jan 25, 2022 Form 4 Insider Report for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)

Role
Chief Operating Officer, Nucleic Acid Production
Signature
/s/ Kurt Oreshack, by power of attorney for Brian Neel
Stock symbol
MRVI
Transactions as of
Jan 25, 2022
Transactions value $
$20,288
Form type
4
Date filed
1/27/2022, 03:00 PM
Next filing
Jun 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRVI Class A Common Stock Award $6.56K +286 $22.95 286 Apr 30, 2021 Direct F1
transaction MRVI Class A Common Stock Award $13.7K +598 +209.09% $22.95 884 Oct 31, 2021 Direct F1
transaction MRVI Class A Common Stock Award +17K +1923.08% 17.9K Jan 25, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRVI Employee Stock Option (Right to Buy) Award $0 +31.5K $0.00 31.5K Jan 25, 2022 Class A Common Stock 31.5K $26.32 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 884 shares of Class A Common Stock was also exempt pursuant to Rule 16b-3(c).
F2 Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the Reporting Person's continued employment with the Issuer.
F3 Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

Chief Operating Officer, Nucleic Acid Production